With investigators at Michigan State University, CDC is participating in cooperative research that builds on an NIH-funded, multi-ethnic community-based study of women from 52 prenatal clinics in 5 Michigan communities. The work of the CDC cooperative agreement expanded the Pregnancy Outcomes & Community Health (POUCH) study to evaluate in an integrated way, the social, clinical, and genetic biological factors associated with preterm birth. In 2005, the NIH Maternal Fetal Medicine Network published results of a clinical trial that found that weekly injections of 17-alpha hydroxyprogesterone caproate (17P) was associated with a significant reduction of preterm birth among women with a history of prior preterm birth. To identify ways to translate these findings into clinical practice, and public health programs, CDC is participating in cooperative research with the University of Cincinnati to evaluate factors associated with acceptance of, use of, and adherence to 17P in the context of routine obstetrical care. The study will also investigate progesterone receptor genes of mothers and infants to explore possible mechanisms of action of 17P. CDC researchers with collaborators from the American College of Obstetricians and Gynecologists, conducted a survey among obstetricians regarding their knowledge, beliefs, and practices regarding the use of 17-hydroxyprogesterone caproate (17P) for the prevention of preterm birth. The survey focused on provider use, drug availability, and patient acceptance and adherence. A collaborative project with University of Kansas, University of Tennessee at Memphis, and CDC is investigating oxygen independent and oxygen dependent defense mechanisms of the lower and upper genital tract and genes associated with regulating the inflammatory cascade. The study of genomics and proteomics will explore if cervico-vaginal biomarkers associated with altered innate immunity can be used to identify women at risk weeks or months before onset of preterm delivery. The vast majority of severe infant morbidity and mortality associated with
preterm birth is due to very preterm birth (less than 32 weeks gestation).
Information from large, population-based cohorts is needed to evaluate
genetic, clinical, and social factors associated with very preterm birth and
racial disparities in maternal and infant health. In collaboration with the
California Department of Health Services, California Birth Defects and
Monitoring Program, and the March of Dimes, CDC is investigating the risk for very preterm birth
using an existing large biobank of blood specimens from routine testing of
pregnant women and infant blood spots from newborn screening. The biobank is
linked to clinical information from medical record review, birth certificate
data, prenatal screening data, newborn screening data and geocoded data on
neighborhood stressors. Genomic investigations will focus on endocrine and
inflammatory pathway genes. In this way, social and biomedical factors and
gene-environment interactions associated with very preterm birth can be
evaluated among black, Hispanic, and white infants. Because of the large
size of the biobank utilized for this study (specimens from approximately
600,000 births), this is a unique opportunity to examine the risk factors
for very preterm birth, the contribution of both maternal and infant genetic
factors, and factors in multiple racial/ethnic groups.
Page last reviewed: 11/25/08 |
|
|
||||||||||||
|